It might seem odd to use a tiny sea creature to explore human genetics. However, as recently reported on Shamini Bundell’s Nature Podcast, marine organisms known as sea squirts may shed light on the origins of vertebrate animals – including humans. That research involved studying missing genes, which could be a significant factor in positive …
Medicare: Rising Premiums and Novel AD Drugs
Medicare recently announced that its Part B outpatient premium will increase by $21.60 per month in 2022. The increase marks one of Medicare’s largest premium jumps on record – but, interestingly enough, one drug is responsible for about half of that cost increase: an Alzheimer’s disease (AD) drug called Aduhelm™. What is the connection between …
How Congress Could Regulate Medicare Drug Prices
Infographics Prescription drug costs continue to be a concern for many Americans. But now, as Congress works to finalize President Biden’s Build Back Better social spending plan, House Democrats have reached a deal that could put some patients’ minds at ease. The measure would potentially curb prescription drug costs, allowing the government to negotiate prices …
Aiding in the Development of Cardiovascular Drugs
According to the World Health Organization, cardiovascular disease is the leading cause of death in the United States and worldwide. In fact, about 17.9 million people die from cardiovascular disease each year, accounting for an estimated 31 percent of deaths worldwide. Yet despite cardiovascular disease being a continual, significant threat to human health, investment in …
QPS Physician Nutte Van Belzen Wins 2019 Young Entrepreneur Award
Entrepreneur Nutte Van Belzen of CC Diagnostics recently won the 2019 Jonge Ondernemingsprijs (Young Entrepreneur Award). Van Belzen also happens to work as a part-time physician at QPS Netherlands, located in Groningen. A wonderful surprise, this award is a reflection of Van Belzen’s hard work and ambitious spirit. What is the Young Entrepreneur Award? The …
Establishing Preclinical Leadership in Asia with the Addition of Mini Pig Studies
Suitable animal models are an unavoidable necessity in the testing and development of new pharmacological agents. QPS has an extensive history of conducting studies in rodents and dogs and has maintained consistent full accreditation with the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) at all of our facilities where animals are …
Establishing Leadership in Asia with SEND
As a pioneer with the Standard for Exchange Nonclinical Data (SEND) system in Asia, QPS Taiwan CTPS has taken a leadership role in implementing and using the SEND data format. The FDA Guidance Document from March 2019, Study Data Technical Conformance Guide, states on page 16 that, “The Standard for Exchange of Nonclinical Data (SEND) …
QPS Missouri Collaborates with Local Agency to Bring Birthday Celebrations to Underserved Children
Wish I May is a volunteer-run 501(c)(3) non-profit organization in the Springfield, Missouri, community striving to make a difference one child and one birthday at a time. The organization provides ‘Happy Birthdays’ to underprivileged children, between the ages of 1 to 15 years, in Greene County, Missouri. Wish I May reaches out to families who may …
QPS Celebrating Sustained Growth in Asia
Did you know that 23.6 percent of the world’s pharmaceutical companies are now located in Asia? That’s up from 20.5 percent in 2018 – a substantial jump for a single year, solidifying Asia’s reputation as a thriving biotech and pharmaceutical research hub. Thousands of small biotech companies around the world are turning to Asia for …
Power Women in Business Development at QPS Netherlands
Two power women currently ‘man’ the Business Development (BD) department at QPS Netherlands, in close collaboration with the Head of BD, Edwin van Vulpen, MBA, Senior Director BD. Spotlight on Sandra Achterhof After graduating, I worked in the pharmaceutical industry for 7 years covering different roles in sales before joining an engineering company, where I …
